| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
137 |
| Employees |
105 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-223 |
| Cash Flow (TTM) (Millions $) |
276 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Iveric Bio Inc is a publicly traded biopharmaceutical company that is focused on the development of innovative treatments for patients suffering from diseases affecting the retina of the eye. The company is headquartered in New York City, New York, and has research and development facilities in Durham, North Carolina.
Iveric Bio Inc is driven by a mission to develop innovative therapies that address unmet medical needs of patients suffering from rare and serious ophthalmic diseases. The company's primary area of focus is on developing treatments for age-related macular degeneration, a leading cause of blindness in the elderly population.
The company's lead product candidate, Zimura, is an investigational complement factor C5 inhibitor for the treatment of geographic atrophy, a severe form of dry age-related macular degeneration. Zimura is designed to eliminate the alternative complement pathway hyperactivation that is responsible for retinal cell death, which is the underlying cause of geographic atrophy.
Iveric Bio Inc leverages its proprietary understanding of the complement system, and has invested heavily in the discovery and development of complement inhibitors that target specific complement pathway components. The company is actively researching additional complement inhibitors that may be useful in treating a variety of ophthalmic diseases.
In addition to its focus on age-related macular degeneration, Iveric Bio Inc is exploring the potential of gene therapy and stem cell therapy in the treatment of inherited retinal diseases such as Stargardt disease and Leber congenital amaurosis.
Overall, Iveric Bio Inc is driven by a commitment to utilizing the latest advances in science and technology to develop innovative and effective treatments for patients suffering from ophthalmic diseases. The company remains firmly dedicated to conducting world-class research and clinical trials, and collaborating with top-tier academic institutions and industry leaders to advance the development of ophthalmic treatments that have the potential to improve the lives of millions of patients around the world.
Company Address: 8 Sylvan Way Parsippany, 7054 NJ
Company Phone Number: 474-6755 Stock Exchange / Ticker: NASDAQ ISEE
|
%
3.24% 